A5003024610- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- Ovarian cancer diagnosis and treatment
- Cancer Genomics and Diagnostics
- Radio Frequency Integrated Circuit Design
- Intraperitoneal and Appendiceal Malignancies
- Lung Cancer Treatments and Mutations
- Microtubule and mitosis dynamics
- TGF-β signaling in diseases
- Colorectal and Anal Carcinomas
- Genetic factors in colorectal cancer
- Angiogenesis and VEGF in Cancer
- Renal cell carcinoma treatment
- Gastric Cancer Management and Outcomes
- Radiomics and Machine Learning in Medical Imaging
- Poisoning and overdose treatments
- Pancreatic and Hepatic Oncology Research
- Cancer Mechanisms and Therapy
- Colorectal Cancer Surgical Treatments
- Opioid Use Disorder Treatment
- Cancer Cells and Metastasis
- Hepatocellular Carcinoma Treatment and Prognosis
- Intestinal and Peritoneal Adhesions
- Pain Management and Opioid Use
- Cancer therapeutics and mechanisms
The Christie NHS Foundation Trust
2021-2024
Nepean Hospital
2022
Westmead Hospital
2022
Cancer Australia
2022
Blacktown & Mount Druitt Hospital
2019-2020
Westmead Institute
2020
Abstract Monthly long-acting injectable buprenorphine (LAI-BUP) is a treatment option for moderate to severe opioid use disorder. Safe administration of LAI-BUP requires preexisting tolerance prevent sedation and respiratory depression. In the event adverse medication effects including oversedation, can be surgically excised up 14 days after (https://www.sublocadehcp.com/dosing-administration). However, manufacturer does not provide guidance on proper procedure excision, no case reports have...
The identification of clinically viable strategies for overcoming resistance to platinum chemotherapy in lung adenocarcinoma has previously been hampered by inappropriately tailored vitro assays drug response. Therefore, using a pulse model that closely mimics the vivo pharmacokinetics therapy, we profiled cisplatin-induced signalling, DNA-damage and apoptotic responses across panel human cell lines. By coupling this data real-time, single-cell imaging cycle apoptosis provide fine-grained...
Abstract Introduction Bevacizumab improves survival outcomes in women diagnosed with epithelial ovarian cancer (EOC). Pre-clinical data showed that the c-MET/VEGFR-2 heterocomplex negates VEGF inhibition through activation of c-MET signalling, leading to a more invasive and metastatic phenotype. We evaluated clinical significance VEGFR-2 co-localisation its association pathway-related single nucleotide polymorphisms (SNPs) participating phase 3 trial, ICON7 (ClinicalTrials.gov identifier:...
Cytotoxic chemotherapy for ovarian cancer can be augmented by co-administration of vascular endothelial growth factor inhibitors but these are contraindicated in patients with bowel obstruction due to the risk gastrointestinal perforation. We evaluated safety and feasibility paclitaxel plus cediranib treat platinum-resistant at malignant obstruction. A phase II trial included eligible between March 2018 February 2021, identified clinical symptoms radiographic factors Cediranib (20 mg/day)...
Despite advances in immunotherapy and targeted therapy, platinum-based chemotherapy remains crucial for many patients with advanced non-small cell lung cancer (NSCLC). Resistance to platinum is common, predictive biomarkers are needed tailor treatment likely respond. In vitro evidence implicates the transforming growth factor-β (TGF-β) superfamily ligands activin-A differentiation factor 11 (GDF-11) innate resistance. We performed a validation study assess their utility as of response...
<div>AbstractPurpose:<p>A single maintenance course of a PARP inhibitor (PARPi) improves progression-free survival (PFS) in germline <i>BRCA1/2</i>-mutant high-grade serous ovarian cancer (g<i>BRCA</i>m-HGSOC). The feasibility second PARPi was unknown.</p>Patients and Methods:<p>Phase II trial with two entry points (EP1, EP2). Patients were recruited prior to rechallenge platinum. relapsed, g<i>BRCA</i>m-HGSOC enrolled at EP1 if...
<div>AbstractPurpose:<p>A single maintenance course of a PARP inhibitor (PARPi) improves progression-free survival (PFS) in germline <i>BRCA1/2</i>-mutant high-grade serous ovarian cancer (g<i>BRCA</i>m-HGSOC). The feasibility second PARPi was unknown.</p>Patients and Methods:<p>Phase II trial with two entry points (EP1, EP2). Patients were recruited prior to rechallenge platinum. relapsed, g<i>BRCA</i>m-HGSOC enrolled at EP1 if...
<p>Supplementary Methodology.</p>
<p>Kaplan Meier curves.</p>
<p>Cell-free circulating DNA yields at each time point.</p>
<p>Functional homologous recombination repair.</p>
<p>BRCA2 reversion mutation detected in cell-free circulating DNA from patient 16.</p>
<p>Cell-free circulating DNA copy-number profiles.</p>
<p>Cell-free circulating DNA copy-number profiles.</p>
<p>Cell-free circulating DNA yields at each time point.</p>
<p>Kaplan Meier curves.</p>
<p>Supplementary Methodology.</p>